JAN 15, 2018 09:44 AM PST

Using Glowing Sea Creatures' Enzymes to Test Cancer Therapies

WRITTEN BY: Julia Travers

Living beings that glow are described as being “bioluminescent.” An enzyme or biological catalyst called luciferase makes fireflies, deep sea dwellers and other organisms glow or bioluminesce. Researchers from the Keck School of Medicine of the University of Southern California (USC) have discovered that luciferase can be used to measure whether a cancer therapy is killing off cancer cells, along with how efficiently it does so. With the help of this glow-producing natural enzyme, they were able to detect the death of a single cancer cell quickly -- within a half-hour.

bioluminescent organism, credit: USC

This method, called the Matador assay (test) has great potential for evaluating the efficacy of various cancer treatments, especially immunotherapies. Through immunotherapy, a patient’s immune system is utilized, optimized and/or engineered to be more effective in taking out tumors. “[T]he methods for testing immunotherapies are not ideal,” says corresponding author and Professor of Medicine at the Keck School, Preet M. Chaudhary, M.D., Ph.D.

"Radioactive chromium release assay is the gold standard for testing whether an immunotherapy kills cancer cells,” he explains. This process measures the breakdown of target cell membranes and the death of the cells through the use of radioactive chromium. “This method is expensive, complicated and requires special disposal practices,” Chaudhary says, adding that other similar methods also possess these kinds of limitations, along with being slow. In contrast, Chaudhary and his team say the Matador assay is an inexpensive, precise, single-step and fast option.

Deep sea shrimp and small crustaceans with markedly bright bioluminescence were chosen as the source of luciferase for the project. The luciferases leak out of dying cells and the changing luminescence can be gauged with a luminometer, which measures light. The study abstract states, “The assay involves expression of a luciferase of interest in target cells in a manner so that it is preferentially retained within the healthy cells but is either released from dead and dying cells or whose activity can be preferentially measured in dead and dying cells.”

The researchers used this assay on acute myelogenous leukemia, myelogenous leukemia, Burkitt's lymphoma and solid tumor cells that were treated with several immunotherapies: CAR-T cells, bispecific T-cell engagers and monoclonal antibodies. The Matador assay could detect the death of a single cancer cell, and a USC press release states this is “a level of sensitivity far exceeding existing assays.”

Chaudhary says the new test can detect cell death “in as little as 30 minutes.” He conveys this rapidity will “ultimately translate to more expedient treatments for patients getting cellular immunotherapies such as CAR-T cells.” CAR-T cells -- chimeric antigen receptor-T-cells -- are immune cells that have been engineered to attack tumors more successfully.

Chaudhary thinks the new method could be useful in cellular therapy manufacturing, biomedical research, screening other anticancer agents and possibly also for measuring environmental toxins.

“Development and characterization of a novel luciferase based cytotoxicity assay,” was published in the journal Scientific Reports in 2018.

About the Author
  • Julia Travers is a writer, artist and teacher. She frequently covers science, tech and conservation.
You May Also Like
OCT 16, 2019
Cancer
OCT 16, 2019
Combining Breast and Lung Cancer Drugs to Overcome Treatment Resistance
The efforts to overcome cancer’s ability to evolve and resist treatment take many forms and comprise a vital and active branch of contemporary cancer...
OCT 16, 2019
Cell & Molecular Biology
OCT 16, 2019
Insight Into a DNA Damage Sensor That Orchestrates Repair
Simple cell functions like division or metabolism can lead to DNA damage, which can also occur because of normal exposure to the sun or noxious agents....
OCT 16, 2019
Cancer
OCT 16, 2019
The golden future of cancer treatment
A study published recently in Chemistry -- A European Journal features research on the golden cancer treatments of the future – literally. Current me...
OCT 16, 2019
Cancer
OCT 16, 2019
Can eating mushrooms reduce the risk of prostate cancer?
Now here’s a question: have you eaten your mushrooms yet today? Although mushrooms may not be one of the typically-touted snacks in the healthcare wo...
OCT 16, 2019
Genetics & Genomics
OCT 16, 2019
Breast Cancer Drug Increases Survival for Prostate Cancer Patients
A breast cancer drug is better at treating advanced prostate cancer in some men than current therapies, a clinical trial shows....
OCT 16, 2019
Cancer
OCT 16, 2019
It's not all bad: cancer and aging
Research published recently in the journal Aging Cell highlights the complexities of the interactions that occur during the aging process from the angle of...
Loading Comments...